References: 1. Wells AF, Edwards CJ, Kivitz AJ, et al. Apremilast Monotherapy as the First Systemic Treatment in DMARD-Naïve Patients With Psoriatic Arthritis: 3-Year Treatment Results. Presented at: the Annual European Congress of Rheumatology EULAR 2016; 8–11 June 2016; London, UK. 2. Edwards C, Wells A, Adebajo A, et al. Apremilast, an Oral Phosphodiesterase 4 Inhibitor, is Associated with Long-Term (52-Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Results from the Palace 4 Phase 3, Randomized, Controlled Trial. Ann Rheum Dis. 2014;73:735.